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ABSTRACT
p63 is a developmentally regulated transcription
factor related to p53, which activates and represses
specific genes. The human AEC (Ankyloblepharon–
Ectodermal dysplasia-Clefting) and EEC
(Ectrodactyly–Ectodermal dysplasia–Cleft lip/palate)
syndromes are caused by missense mutations of
p63, within the DNA-binding domain (EEC) or in the
C-terminalsterilealphamotifdomain(AEC).Weshow
here that p63 represses transcription of cell-cycle
G2/M genes by binding to multiple CCAAT core pro-
moters in immortalized and primary keratinocytes.
The CCAAT-activator NF-Y and DNp63a are associ-
ated in vivo and a conserved a-helix of the NF-YC
histone fold is required. p63 AEC mutants, but
not an EEC mutant, are incapable to bind NF-Y.
DNp63a, but not the AEC mutants repress CCAAT-
dependent transcription of G2/M genes. Chromatin
immunoprecipitation recruitment assays establish
that the AEC mutants are not recruited to G2/M
promoters, while normally present on 14-3-3s,
which contains a sequence-specific binding site.
Surprisingly, the EEC C306R mutant activates tran-
scription. Upon keratinocytes differentiation, NF-Y
and p63 remain bound to G2/M promoters, while
HDACs are recruited, histones deacetylated, Pol II
displaced and transcription repressed. Our data
indicate that NF-Y is a molecular target of p63 and
that inhibition of growth activating genes upon
differentiation is compromised by AEC missense
mutations.
INTRODUCTION
p63 is a transcription factor homologous to p53 and p73 (1,2).
It binds to DNA in a sequence-speciﬁc way in the promoter
and enhancers, activating genes that block cell-cycle progres-
sion and promote apoptosis. Unlike p53, p63 and p73 are not
ubiquitously expressed, and are involved in separate develop-
mentalprocesses.Threeproteinmotifsaresharedbythehomo-
logues: a transactivation domain—TA—at the N-terminal,
a central DNA-binding domain and a tetramerization domain.
There are two different transcription initiation sites generating
proteins containing, TA, or lacking, DN, an activation domain.
Furthermore, the 30 end of the gene is involved in alternative
splicing, which gives rise to three isotypes, alpha, beta and
gamma; hence, six p63 isoforms are potentially present in
cells, at various levels of relative expression. The C-terminal
of p63 and p73 contains the sterile alpha motif (SAM) domain,
found in >40 proteins involved in developmental regulation
(3). It consists of ﬁve helices packed into a compact globular
domain representing a protein–protein interaction module (4).
The association of ectodermal dysplasia with cleft lip/
palate is found in several clinical entities often associated
with dominant transmission (5,6). The Hay–Wells
(Ankyloblepharon–Ectodermal dysplasia-Clefting) AEC, the
Ectrodactyly–Ectodermal dysplasia–Cleft lip/palate (EEC)
and the Split Hand/split Foot Malformation syndromes
show clinical variability, with sparse hair, dry skin, philose-
baceous gland dysplasia and oligodontia. Patients with the
AECsyndromedonotshowectrodactylyorotherlimbdefects,
but have ankyloblepharon, fused eyelids, and severe scalp
dermatitis, unlike EEC patients, who have widespread defects
in ectodermal development, but less severe skin alterations.
These syndromes are caused by mutations in the p63 gene (5).
The vast majority of the mutations found in EEC syndromes
are missense mutations generating amino acid substitutions in
the residues predicted to contact DNA [(5,7) and references
therein]. All isoforms of p63 are affected by these alterations.
On the other hand, mutations causative of the AEC syndrome
are all missense mutations falling within exon 13, coding for
most of the SAM domain; thus, only the p63a isoforms are
affected. Interestingly, skin biopsies documented p63 staining
in the differentiating cells of the suprabasal layer, where p63
is normally absent (6). Genetic experiments in mice conﬁr-
med the speciﬁcities of the p63 gene function and are well in
agreement with the phenotypes in humans; mice lacking p63
die soon after birth with severe defects in limb, craniofacial
and skin development (8,9). Additional clues to the function
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doi:10.1093/nar/gkj477of p63 came from zebraﬁsh, where the dominant isoform,
corresponding to DNa, is required for epithelial development
(10,11). The DNa is apparently the most abundant iso-
form found in keratinocytes, and indeed p63 has been
shown to be a marker of epithelial stem cells of the skin
and of the ocular limbus (12,13). Altogether, these data estab-
lish p63 as a master regulatory gene of skin development
[reviewed in (14,15)].
In addition to being an activator, p63 can also repress tran-
scription (16–19). p53 and p73 negatively regulate the expres-
sion of G2/M regulators such as CDC25B, CDC25C, Cyclin
B1, Cyclin B2, Cdc2, Check 2, securin and Topoisomerase IIa
upon DNA-damage (20–29). In these studies, the negative
activity was shown to be exerted indirectly through the mul-
tiple conserved CCAAT boxes; in other reports SP1, or direct
p53 binding were implicated in Cyclin B1 and CDC25C
repression (27,30). As for p63, it was shown to have opposite
effects on cdc2 and HSP70, in both cases acting on CCAAT
boxes (22,31).
The CCAAT box is bound and regulated by the trimeric
factor NF-Y, composed of three subunits, NF-YA, NF-YB and
NF-YC, all necessary for DNA-binding (32). NF-YB and NF-
YC contain histone fold motifs (HFMs) common to all core
histones; dimerization is essential for NF-YA association and
sequence-speciﬁc DNA binding (33). A recent bioinformatic
analysis of cell-cycle promoters showed a remarkable and
speciﬁc abundance of CCAAT boxes in promoters regulated
during the G2/M phase (34). Chromatin immunoprecipitation
(ChIP) experiments determined that NF-Y is dynamically
bound in the different phases of the cell cycle (35). Finally,
association of NF-Y to p63 has been detected (31,36).
To shed light on p63 repressive function in the CCAAT
promoters circuitry, we investigated the relationship between
p63 and NF-Y in human keratinocytes with protein–protein
interaction, transfection and ChIP experiments, using wt p63
and AEC/EEC-derived mutants.
MATERIALS AND METHODS
Immunoprecipitation analysis
The AEC mutants were described in Ref. (6). NF-YC aC
mutants were produced in the backbone of the His-YC5
mutant as detailed in Ref. (37). Immunoprecipitations were
performed as in Ref. (20); 50–100 ng of recombinant proteins
were incubated in 100 ml of NDB 100 [100 mM KCl, 20 mM
HEPES, pH 7.9, 0.1% NP40, 0.5 mM EDTA and 1 mM
phenylmethlysulfonyl ﬂuoride (PMSF)] rotated for 2 h at
4 C and then added to 10 ml of ProteinG–Sepharose to
which 5 mg of the anti-NF-YC antibodies had been bound
previously. Incubation was pursued for 2 h at 4 C, unbound
material recovered after centrifugation and the beads washed
with NDB100. SDS buffer was added, the samples boiled
at 90 C for 50 and loaded on SDS gels. Western blots were
performed according to standard procedures with the indicated
primary antibody (anti-YB, anti-YC and anti-p63 4A4). For
in vivo interactions, SaoS2 cells were transfected in 24-well
plates with 100 ng of the NF-Y and p63 eukaryotic expres-
sion vectors. The cells were harvested after 24 h in lysis
buffer (50 mM Tris–HCl, pH 8, 120 mM NaCl, 2 mM DTT,
10 mg/ml leupeptin and 10 mg/ml aprotinin, 1 mM PMSF,
0.5% NP40). Immunoprecipitations were performed by
incubating whole-cell extracts with 2 mg of the relevant
antibodies, with ProteinA–Agarose (Sigma) at 4 C overnight.
The beads were washed twice with NDB100 plus protease
inhibitors, eluted in SDS buffer and loaded on 12%
SDS–polyacrylamide gels.
Chromatin immunoprecipitations
ChIPassayswereperformedasdescribed(20,35).HaCaTcells
(0.5/1 · 10
8) were washed in phosphate-buffered saline (PBS)
andincubatedfor10minwith 1%formaldehyde;afterquench-
ing the reaction with Glycine 0.125 M, cells were sonicated
and chromatin fragments of an average length of 1 kb recov-
ered by centrifugation. Immunoprecipitations were performed
with ProtG–Sepharose (KPL) and 3–5 mg of the indicated
antibodies: NF-YB puriﬁed rabbit polyclonal; p63 (4A4),
anti-acetyl-H3, anti-acetyl-H4 (Upstate), anti-Pol II (Santa
Cruz) and anti-HDAC1 (Sigma). Anti-HDAC4 (Active
Motif), control anti-Flag (Sigma). ProtG–Sepharose was
blocked twice at 4 C with 1 mg/ml salmon sperm DNA sheared
at 500 bp length and 1 mg/ml BSA, for 2 h and overnight.
Chromatin was precleared by adding ProtG–Sepharose for
2ha t4  C, aliquoted and incubated with the antibodies over-
night at 4 C. Semi-quantitative PCRs were performed with
the following primers: Topoisomerase II a 50-CCTGCACA-
CTTTTGCCTCAG-30,5 0-GACCAGCCAATCCCTGACTC-30;
CDC25C 50 GCTGAGGGAACGAGGAAAAC-30;5 0-CG-
CCAGCCCAGTAACCTATC-30; Cyclin B1 50-TGTCA-
CCTTCCAAAGGCCACTA-30,5 0-AGAAGAGCCAGCCT-
AGCCTCAG-30; Cyclin B2 50-AGAGGCGTCCTACGTCT-
GCTTT-30,5 0-ATTCAAATACCGCGTCGCTTG-30; OGG1
50-CCGAGTGCAGACAATCCCGG-30;5 0-CTCCTTGCGA-
CTTATCTTCTCC-30; PLK 50-GAAAGGGAGAAACCCCG-
AAG-30,5 0-GCTCCTCCCCGAATTCAAAC-30; Luciferase
50-TTGCTCTCCAGCGGTTCCAT-30. HSP70 forward
50-GGCGAAACCCCTGGAATATTCCCGA-30 and reverse
50-AGCCTTGGGACAACGGGAG-14-3-3s50-CTCACTAC-
CTCAAGATACCC-30;5 0-CACAGGCCTGTGTCTCCC-30.
Transient transfections
SaoS2 cells (2.5 · 10
4) were transfected with Lipofectamine
(Gibco-BRL) using 0.1 mg of Cyclin B2-Luciferase (23),
cdc2-CAT (gift of G. Piaggio, IRE, Rome, Italy), Topo II a
Luciferase (Gift of M. Broggini, Negri Institute, Milan, Italy)
or Calreticulin Luciferase vectors, 100 ng of the p63 express-
ing plasmids (Obtained from H. Van Bokhoven, Leyden, The
Netherlands), 50 ng of NbGAL and carrier plasmid to keep the
total DNA concentration constant at 1 mg. Cells were recov-
ered 36 h after transfection, resuspended in TEN (150 mM
NaCl and 40 mM Tris–HCl, pH 7.4) for measurements of
CAT activity, or Lysis buffer (Triton-X 1%, Glycil-glycine
25 mM, MgSO4 15 mM and EGTA 4 mM) for luciferase.
b-galactosidase was assayed to control for transfection efﬁ-
ciencies. Three to four independent transfections in duplicate
were performed. SDs were calculated as <20% of the relative
levels.
The ChIP analysis performed in Figure 6 was carried out in
SaoS2 (15 cm plates, 6 · 10
6 cells) transfected with the p63
plasmids (10 mg) and the Cyclin B2 Luciferase vector (10 mg).
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analysis was performed as described above.
Immunofluorescence
Cells were washed twice in PBS at room temperature, ﬁxed in
cold methanol/acetone for 20 and permeabilized with 0.05%
TritonX 100 in PBS for 50. Samples were preincubated with
1% BSA in PBS for 15 min and then incubated overnight at
4 C with the following primary antibodies diluted 1:100 in
PBS plus BSA 1%: anti-CK8-18 (Santa Cruz sc-8020); anti-
CK1 (Covance PRB-149P); anti-p63 (Dako 4A4). Cells were
then washed twice with PBS and incubated for 15 min at room
temperature in PBS plus BSA before a further incubation,
60 min at room temperature in the dark, with Hoechst and
the relative secondary antibodies: FITC anti-rabbit 1:200
(F7512; Sigma), TRITC anti-mouse 1:150 (T5393; Sigma).
Slides were taken with a Zeiss-Axioskop microscope.
RT–PCR analysis
RNA was extracted using an RNA-Easy kit (Quiagen,
Germany), according to the manufacturer’s protocol, from
HaCaT cells. For cDNA syntesis, 2 mg of RNA were used
with M-MLV-RT kit (Invitrogen). Semi-quantitative PCR
analysis was performed with primers speciﬁc for the different
p63 isoforms. TA and DNp63a reverse, 50-ACTTGCCAGAT-
CATCCATGG-30; TA and DNp63b reverse, 50-TCAGACTT-
GCCAGATCCTG-30; TA and DNp63g reverse, 50AAGCTC-
ATTCCTGAAGCAGG-30; DNp63 forward, 50-CCAGACT-
CAATTTAGTGAGC-30; TAp63 forward, 50-TTAGCATG-
GACTGTATCCGC-30. CCNB1 forward, 50-CACTTCCTT-
CGGAGAGCATC; reverse, 50-CAGGTGCTGCATAACTG-
GAA-30. CCNB2 forward, 50-CAGTTCCCAAATCCGAG-
AAA-30; reverse, 50-TCTGAGACAAGCAGGAAGCA-30.
CDC25C forward, 50-AAAGGCGGCTACAGAGACTTC-30;
reverse, 50-AGCCCAGAGAGAAAGAGTTGG-30. NF-YB
forward, 50-AGGTGCCATCAAGAGAAACG-30; reverse,
50-TGTTGTTGACCGTCTGTGGT-30; Topo II a forward,
50-GCCCTCCTGCTACACATTTC-30; reverse, 50-AACACT-
TGGGCTTTACTTCACTT-30; HSP70 forward, 50-TTTCGA-
GAGTGACTCCCGTT-30; reverse, 50-AAAGGCCAGTGC-
TTCATGTC-30.
RESULTS
DNp63a is associated to G2/M promoters in vivo
It is generally assumed that the major, if not the sole isoform
present in HaCaT keratinocytes is DNp63a (2,38). To conﬁrm
this point in our system, we performed RT–PCR analysis,
using isoform-speciﬁc combinations of oligonucleotides.
PCR ampliﬁcations show that while DNp63a was promptly
visible at a low number of cycles, the p63b or p63g isoforms
were far less abundant and the TAp63 isoforms essentially
absent (Figure 1A). At the protein level, western blot analysis
conﬁrmed this ﬁnding, since a single polypeptide with a MW
consistent with that of DNp63a was visualized (Figure 1B).
HaCaT cells can be induced to differentiate into more mature
keratinocytes by adding calcium and eliminating serum from
the medium (39,40). We checked this with positive and nega-
tive markers by immunoﬂuorescence analysis. In accordance
with expectations, CK1 increases, while CK8-18 decreases
after 72 h in differentiation medium, whereas staining with
p63 was positive before and after (Figure 1C). RT–PCR anal-
ysis indicated that the DNb isoform increases after differen-
tiation. Note that growing cells under calcium-free medium,
which is required for optimal differentiation, increases the
levels of the DN b and g isoforms in undifferentiated cells.
These differences notwithstanding, the DNa is still very abun-
dant after differentiation and the predominant isoform in all
conditions tested. The TA isoforms are essentially absent in
any conditions.
Recent ChIP experiments performed in our laboratory
established that p53 binds to G2/M promoters in mouse
NIH3T3 ﬁbroblasts in the absence of DNA-damage and of
p53 binding sites (20). Given the similarities, it is possible
that p63 behaves similarly in the appropriate cellular context,
such as keratinocytes. We prepared HaCaT chromatin and
performed ChIPs with the 4A4 anti-p63 antibody. As a posi-
tive control, we used an anti-YB antibody. As shown in
Figure 2, all G2/M promoters—Cyclin B1, Cyclin B2,
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Figure 1. HaCaTcells expressDNp63a.(A) RT–PCRanalysisofHaCaT cells
exponentially growing in DMEM medium. Specific oligonucleotides for each
ofthesixmajorisoformswereusedwithincreasingPCRcycles.Fordetailssee
Materials and Methods. (B) Western blot analysis of HaCaT nuclear extracts
with the 4A4 antibody, which recognizes all p63 isoforms; a major band
corresponding to the DNa isoform is predominant. (C) Immunofluorescence
analysis of differentiation markers. HaCaT cells were grown in CaCl2-free
medium containing 10% foetal calf serum (FCS) (0 h, left panels) and in
1.2 mM CaCl2, 0.1% FCS for three days (72 h, right panels). After fixation,
cells were stained with anti-Cytokeratin 1, anti-Cytokeratin 8–18 differentia-
tion markers, as well as anti-p63 antibodies. (D) RT–PCR analysis of p63
isoforms in HaCaT keratinocytes. mRNA was extracted from cells as in (C).
Notethatundertheseconditions,HaCaTcellstendtohavehigherlevelsofDNb
and g isoforms. Nevertheless, the DNa isoform is still predominant.
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for p63. On the other hand, PLK, a promoter with a single
CCAAT, was negative for p63, in line with recent p53 ChIP
experiments (20). Two additional p63 antibodies yielded the
same results (data not shown). NF-Y was positive, an expected
result, since PLK is known to be activated by NF-Y (41).
We controlled a CCAAT-less cell-cycle regulated promoter,
YBL1/Pole3; none of the antibodies tested signiﬁcantly
immunoprecipitated this target (lower panel), conﬁrming
the speciﬁcity of our ChIP procedure. We then switched to
a normal system, using primary human keratinocytes for pre-
paration of chromatin. In this setting, we added an anti-p53
antibody to our ChIPs; both p63 and p53 were positive on
G2/M promoters, while negative on CCAAT-less, or single
CCAAT promoters (Figure 2, right panels). Therefore, in
immortalized or primary keratinocytes, p63 is associated
in vivo to promoters of crucial cell-cycle regulatory genes
containing double CCAAT boxes, in the absence of a p53-
binding sequence.
Effects of p63 on CCAAT-dependent transcription
Having shown a negative role of p53 on multiple CCAAT-
dependent transcription (20,25), we wished to ascertain
whether p63 would also have a transcriptional effect. We
transfected the Cyclin B2, which contains three functionally
important CCAAT-boxes (23,25), with the TA and DN iso-
forms in the p53 negative SaoS2 cell line, in which low levels
of p63 and p73 are expressed (16,42). Figure 3A shows that
DNp63a represses the promoter. Parallel transfections with
four AEC mutants had no signiﬁcant effect on transcription.
In parallel, we transfected a mutant Cyclin B2 construct, in
which all CCAAT boxes were substituted with random
pentanucleotides; this construct shows a considerably lower
level of activity, but it is still quite active when compared with
a promoter-less Luciferase construct (20). DNp63a had no
effect on the lower activity of the promoter, indicating that
repression is operative as long as the three CCAAT are intact.
A surprising exception was DNp63a T537P, which somewhat
activated the mutant promoter. It should be noted that this
mutant was the only one behaving dissimilarly in repression
assays on the HSP70 promoter (16). As this seems speciﬁc for
Cyclin B2 (see below), the effect was not clariﬁed further.
Similar coexpression experiments were conducted with the
TAp63a versions; none of the vectors showed any effect on
either the wt, or mutant Cyclin B2.
Next, we performed similar experiments with other target
promoters, known for their NF-Y-dependence and repression
by p53: cdc2 and TopoII a (21,22). The former contains two
CCAAT boxes, the latter ﬁve, although in the version we used
here, only the three most proximal CCAAT were present. In
both cases, we observed a clear repression by the DNp63a, but
not by the TA isoform, nor by L518F or T537P, representative
of the AEC mutants used above (Figure 3B). In the case of
Topo II a, we also checked the transcription of a CCAAT-
mutated construct; if anything, p63 showed modest positive
effects, and no change was scored with the T537P. We then
transfected Cyclin B2 with wt and the C306R EEC mutant
(Figure 3C); surprisingly, the mutant showed a clear activation
potential, both in the DN and TA conﬁgurations. The differ-
ence with wt was particularly striking for DN, switching a
repressor into an activator.
To control for the speciﬁcity of these data, calreticulin, a
single CCAAT promoter, was also tested; the p63 vectors had
no effect on the levels of transcription (Figure 3D). Finally, we
checked the expression levels of the transiently transfected
p63 isoforms; as shown in Figure 3E, equal amounts of the
wt and mutants were produced; NF-YB, used as control, was
similarly unaffected. From these data, we conclude that the
speciﬁc negative role of DNp63a on cell-cycle regulated pro-
moters is dependent on (i) intact multiple CCAAT-boxes, and
(ii) an intact p63 SAM domain.
NF-Y–p63 association
It was found recently that p53, and overexpressed p73 and p63
bind to NF-Y in vivo (20,31,36). To conﬁrm these data in a
physiological setting, we immunoprecipitated endogenous
NF-Y and p63 from human primary keratinocytes with anti-
NF-YC and control (anti-Flag) antibodies. The major isoform
is, as in HaCaT, DNp63a. Western blot analysis with anti-p63,
anti-YB and anti-YA antibodies revealed association in the
NF-YC, but not control IPs (Figure 4A). We note that a con-
sistently higher amount of NF-YB was immunoprecipitated, as
compared with NF-YA, some of which remained in the
unbound fraction. We then used NF-Y mutants to pinpoint
the region of interaction on the NF-Y side. Extracts of cells
in which TA (upper panels) or DN (lower panels) p63 was
overproduced were incubated with recombinant NF-Y
mutants. The HFM dimer was sufﬁcient for p63 binding
(data not shown); in particular, the NF-YC aC helix has
been shown to be a docking site for NF-YA, MYC and,
most relevantly here, p53/p73 (20,33,36). We therefore
used single amino acid mutants in this NF-YC domain. We
performed immunoprecipitations with anti-YC antibodies and
western blot analysis with anti-YB, anti-YC and anti-p63.
Figure 4C shows that all mutants are positive for anti-YC,
as well as anti-YB, as expected, conﬁrming that alteration
of the aC has no effect on HFM dimer formation (37).
However, several mutants were negative when probed with
anti-p63: F111S, L114T and I117P. At the 115 position, an
Isoleucine to Proline, but not to Lysine, mutation abolished
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Figure 2. In vivo binding of DNp63a to promoters with multiple CCAAT
boxes. ChIP analysis of growing HaCaT keratinocytes (left panels) and human
primary keratinocytes (right panels) using the indicated anti-NF-YB, anti-p63
(4A4) and anti-53 antibodies.
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mutation. No binding was scored when immunoprecipitating
with a control antibody. Similar results were obtained with the
DNp63a with NF-YB/YC and a representative I115P mutant
(lower panels). These data indicate that the integrity of the NF-
YC aC is crucial for p63 association, since Proline substitu-
tions at positions 115 and 117 severely affect binding, and that
hydrophobic residues are important, as both Phenylalanine
111 and Leucine 114 are required.
AEC mutants, but not an EEC mutant,
fail to associate NF-Y
To map the protein–protein interactions on the p63 side, we
coexpressed TAp63a and NF-Y in vivo and performed
immunoprecipitations with an anti-NF-YC antibody. A robust
interaction was evident (Figure 5B, upper panel), conﬁrming
the experiments shown above. We then coexpressed various
p63 single amino acid mutants derived from AEC patients in
the SAM domain (L518F, G534V, T537P and Q540L) and
assayed them in immunoprecipitation: essentially none was
capable to associate NF-Y. Interestingly, parallel coexpression
of an EEC-derived mutant in the DNA-binding domain,
C306R, was normal in NF-Y association (Figure 5B, lower
panel). The expression of all these mutants was checked in
western blot and all were equally abundant (data not shown
and Figure 3). These data are in agreement with repression
assays and we conclude that all SAM domain mutants, but not
an EEC mutant, loose the capacity to interact with NF-Y in
coexpression assays in vivo.
Figure 3. DNp63a represses Cyclin B2, cdc2 and Topoisomerase a promoters. (A) Functional analysis of the Cyclin B2 promoters [wt and mutated in the three
CCAAT boxes, see Ref. (25)] in SaoS2 cells, cotransfected with the DNp63a (left panel) and TAp63a (right panel) isoforms. The different AEC SAM domain
mutants were cotransfected in parallel, both in the DN and TA configurations. (B) In the middle panels, the indicated wt and AEC DN and TA p63 constructs (wt,
L518FandT537P)weretransfectedwithTopoIIa,wtandCCAAT-mutatedpromoters(leftpanel),ora Cdc2promoterLuciferase plasmid(middlepanel).(C)The
activity of the Cyclin B2 promoter was tested with the p63 EEC C306R mutant, both in the DN and TA configurations. (D) The CCAAT-dependent Calreticulin
promoter was cotransfected with DN and TA p63 expressing vectors. (E) Western blot analysis detailing the relative levels of the wt and p63 mutant proteins
overexpressed, together with endogenous NF-Y to normalize protein levels.
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The loss of repression capacity of the DNp63a AEC mutants
lead us to verify whether the mutants were capable of
interacting with the repressed promoters in vivo. We per-
formed ChIPs by cotransfecting a wt Cyclin B2 Luciferase
reporter and p63 expressing vectors in SaoS2 cells: both the
wt and Q540L p63 were capable to associate to the reporter
when compared with control ChIPs, in which an empty
vector was cotransfected (Figure 6); the DN and TAp63a
behaved similarly. Interestingly, the EEC C306R showed
promoter association. On the other hand, neither the TA nor
the DNp63a L518F associated with the transfected Cyclin B2
promoter. Although we only cotransfected p63, and not NF-Y
vectors, binding of the latter was evident on the transfected
Cyclin B2 Luciferase reporter, indicating the efﬁcient
association of the endogenous NF-Y (20). Thus, a negative
effect on NF-Y binding as a possible cause of repression, was
ruled out. In parallel, we also checked two endogenous pro-
moters in the same ChIPs, Cyclin B2 and a bona ﬁde p63
target, 14-3-3s (18). That the latter is indeed a p63 target
was conﬁrmed with ChIPs performed in HaCaT cells
(Figure 6, right panel). Interestingly, none of the AEC mutants
was able to associate to the endogenous Cyclin B2
promoter, unlike the TA, DN and the EEC C306R mutants,
in both conﬁgurations (Figure 6, middle panels). Conversely,
all the AEC mutants were bound to 14-3-3s, but not the
C306R. In conclusion, the EEC C306R mutant is indeed
defective in sequence-speciﬁc DNA-binding in vivo,a s
predicted by comparison with the corresponding p53 mutants
isolated in human tumours, and shown with in vitro elec-
trophoretic mobility shift assays (EMSAs) for the TAp63g
isoforms on p53 oligonucleotides (7). p63 AEC mutants
normally bind DNA in a sequence-speciﬁc manner, but they
are incapable to associate to CCAAT promoters. Under
high, non-physiological levels of DNA targets, they behave
somewhat dissimilarly with respect to promoter association:
one, L518F, is totally incapable to promoter association,
the other, Q540L, retaining this capacity only on transfected
targets.
Figure 4. InvivoNF-Y–p63interactions.(A)EndogenousNF-Yandp63wereimmunoprecipitatedfromhumanprimarykeratinocyteswithanti-NF-YCandcontrol
(anti-Flag)antbodies.Load,flowthrough(FT)and bound(B) materialswereloadedon SDSgels andassayedin westernblot analysiswiththeindicated antibodies.
(B) Structure of the NF-YC aC structure (37). The amino acids mutated in the analysis are indicated. (C) The indicated p63-TA or DN- were overproduced in
transfections,andtheNF-YCmutantsindicatedwereproducedinEscherichiacoli,togetherwithrecombinantNF-YB,andassembled.Interactionswereassayedin
immunoprecipitations with in vivo produced wt TAp63a (upper panels with different NF-YC mutants) or DNp63a (lower two panels, with NF-YB/NF-YC and the
NF-YC I115P mutant).
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HaCaT differentiation
We showed recently that p53 and NF-Y are necessary for
repression of G2/M genes following DNA damage. We
used the HaCaT system to understand the role of p63 in dif-
ferentiation. RT–PCR analysis indicates that Cyclin B1/B2,
Topo II a and CDC25C mRNA levels dramatically decrease
after 72 h in differentiation medium (Figure 7A), whereas the
NF-YB mRNA was largely unchanged, as expected from
experiments with other cell types (32). HSP70 and the internal
controlGAPDHalsodidnotchange(Figure7A,lowerpanels).
ChIP analysis were performed in growing and differentiated
HaCaT with different antibodies; NF-Y and p63 were present
before and after, whereas the levels of acetylation of histones
H3 and H4 tails remarkably dropped in Cyclin B2 and
CDC25C, less so in Cyclin B1 (Figure 7B). Consistent with
this, HDAC1 was recruited at 72 h, more prominently on
Cyclin B2 and CDC25; HDAC4 was also, albeit weakly,
detectable (Figure 7B). On the heat inducible HSP70, a
geneshownto beregulated by p63 (31), HDAC1 was observed
in growing and differentiated cells. In keeping with promoter
repression, RNA Pol II was completely absent on Cyclin B1
and decreased in CDC25C and Cyclin B2 (Figure 7B, right
lanes). On HSP70, RNA Pol II, as well as NF-Y and p63, were
present continuously. We notice a decrease in H4, but not H3,
acetylation, which was not investigated further.
Thus, consistent with a role in repression of growth regu-
lating genes, the shut-off of promoter activity after differen-
tiation is concomitant with p63, and NF-Y, remaining stably
bound to the G2/M promoters, while repressive changes are
installed.
Figure 5. NF-Y–p63 interactions: analysis of AEC p63 mutants.
(A) Structure of the p73 SAM domain: the residues corresponding to
AEC mutations in p63 are indicated. (B) Immunoprecipitation analysis
of the different p63 (wt and mutants) transfected in SaoS2 cells with
full-length NF-YB and NF-YC. Extracts were incubated with anti-YC
and control anti-thioredoxin antibodies. Western blot analysis was
performed with anti-p63 (upper panel; Santa Cruz H137), anti-YB and
anti-YC (lower panels) antibodies. L, load; FT, flow through; B, bound
material.
Figure 6. In vivo recruitment of p63 AEC and EEC mutants to Cyclin B2. ChIP analysis of NF-Y and p63 in SaoS2 cells transfected with DN and TA isoforms of
p63-wt,L518F,Q540LandC306R-andthecontrolemptyvector.Togetherwiththep63expressingvector,wecotransfectedtheCyclinB2Luciferaseconstruct.The
PCRs on the transfected templates are performed with a 50 primer for Cyclin B2 and a 30 primer specific for the Luciferase reporter (left panels). The PCRs on the
endogenous Cyclin B2 (middle panels) and 14-3-3s genomic loci (right panels) were performed with the specific oligonucleotides indicated in Materials
and Methods on the same immunoprecipitated DNAs. In the right panel, we performed ChIPs with HaCaT chromatin as in Figure 2, to ascertain the positivity
of the 14-3-3s promoter for p63.
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Genotype–phenotype analysis of human syndromes, knockout
experiments in mice, and genetic data in zebraﬁsh unambigu-
ously pointed to p63 as a master regulator of ectoderm and,
more speciﬁcally, of multi-layered epithelia. Indeed, the DN
isoform is a marker of keratinocytes stem cells. Extrapolating
from our observations on p53, we ﬁnd that p63 associates with
NF-Y, residing on CCAAT-dependent G2/M promoters in vivo
in growing and differentiated cells. Most importantly, it
inhibits transcription, unlike its AEC missense derivatives.
Loss of repression parallels the incapacity to contact NF-Y
and to be recruited on Cyclin B2. Surprisingly, an opposite
phenotype emerged for the DNA-binding mutant EEC, in
terms of NF-Y-binding, promoter recruitment and transcrip-
tional activation.
NF-Y–p53 versus NF-Y–p63 interactions
The requirement of NF-Y for repression of p53 family
members is inferred from several ﬁndings. (i) The elimination
of the CCAAT boxes leads to the abrogation of the negative
effect of DNA-damaging agents, or p53/p73/p63 overexpres-
sion, on promoter function. (ii) In vivo ChIP experiments from
our lab established that p53 is associated to G2/M promoters
in NIH3T3 mouse ﬁbroblasts, and it is activated through
acetylation upon DNA-damage. Moreover, several control
experiments strictly linked the presence of p53 to NF-Y
bound promoters [(20) and references therein]. This picture
is mirrored for p63 in the cells used here, HaCaT and primary
keratinocytes, as representative of a tissue (skin) affected by
p63 mutations in AEC patients and in knock-out mice. HaCaT
cells harbour two DNA-binding mutant alleles of p53. In these
cells, the DNp63a is by far the most abundant, if not the sole
isoform present [(31) and Figure 1). Our ChIP data identify
DNp63a associated to cell-cycle regulatory genes and conﬁrm
that p53 is also bound; importantly, this is observed both in
immortalized and primary keratinocytes, indicating that this is
notanepiphenomenonofimmortalization.ThePLKpromoter,
harbouring only one CCAAT, is devoid of DNp63 (and p53).
Thus, CCAATpromoters are targetednotonlyby p53, but also
by p63; the presence of multiple CCAAT boxes is important
for p63 association. It is possible that p73, in the proper cel-
lular context, behaves similarly, as evidenced by ChIP studies
on the PDGF-b-R (43). In none of these promoters are there
recognizable p53/p63-binding sequences, and the most obvi-
ous hypothesis is that recruitment is obtained through direct
protein–protein interactions with NF-Y. Indeed, endogenous
NF-Y and p63 do interact (Figure 4A). On the NF-Y side, the
aC of the H2A-like NF-YC is required, a stretch clearly dif-
ferent from H2A, centered on the crucial, highly conserved
Phenylalanine 111; a mutation of this residue abolishes
binding to p63, as well as to NF-YA (37). The model resulting
from the NF-YB-NF-YC crystal structure (37) suggests that
multiple NF-Ys might predispose a peculiar, highly bent
DNA structure for p63 association. This could reﬂect the
tetrameric status of p63, needing multiple NF-Y docking
Figure 7. Repression of G2/M genes upon HaCaT differentiation. (A) RT–PCR analysis of G2/M genes in growing (0 h) and differentiated HaCaT cells (72 h).
The constitutive NF-YB and GAPDH transcripts served as internal controls. (B) ChIP analysis of Cyclin B2 promoter in undifferentiated and differentiated HaCaT
cells with the indicated anti-YB, anti-p63 (4A4), anti-Acetyl-H3, anti-Acetyl-H4, anti-HDAC1, anti-HDAC4 and anti-Pol II antibodies.
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cellular conditions, in which multiple CCAAT boxes are
bound.
A simple explanation for promoter repression by p63 was
that it directly inhibits binding of NF-Y to CCAAT. Jung et al.
(22) observed a drastic reduction in NF-Y-binding capacity, as
measured in vitro with EMSAs on the cdc2 promoter, in cells
infectedwithadeno-p63.Thisiscertainlynotthecase inChIPs
for p53 (20) and p73 (36); here, we conﬁrm that even vast
overexpressions of various p63 isoforms do not prevent
endogenous NF-Y to associate to promoters in vivo
(Figure 6). Indeed, endogenous NF-Y is readily capable to
associate to a cotransfected promoter construct. Moreover,
differentiated HaCaT have NF-Y bound to repressed promot-
ers (Figure 7). Finally, we ﬁnd that the effect of p63 overex-
pression on NF-Y binding is quite minute in in vitro EMSAs
(B. Testoni and R. Mantovani, unpublished data). Therefore,
we consider that inhibition of NF-Y DNA binding is not
physiologically relevant to explain promoter repression.
Rather, more complex alterations related to post-
translational modiﬁcations, of p63 and NF-Y, and recruitment
of corepressors are likely to be crucial.
p63 on growth regulating promoters: implications for
the pathogenesis of the AEC syndromes
NF-Y is, to the best of our knowledge, the ﬁrst transcription
factor whose association is altered in p63 AEC missense
mutants. Given its pivotal role for activation of growth-
regulating genes, the lack of binding and promoter association
of these mutants is relevant and could contribute to explain the
pathogenesis of the skin alterations. The key to skin develop-
ment is the a isoforms, DN (15) and TA (14). The DN isoform
is a repressor of p53 activation. In both conﬁgurations, SAM
domain mutations behave as dominant negatives on p53-
activated transcription of artiﬁcial, as well as natural promot-
ers (16,18). The p21 and 14-3-3s promoters are repressed by
DNp63a, and repression is only partially lost in AEC mutants
(18).Here, wealsoﬁndthatthe DN,butnotTAp63aiscapable
to repress Cyclin B2, cdc2 and Topo II a promoters. The DN
versus TA difference in repression could be explained by the
ﬁndings of Serber et al. (44) that intramolecular interactions
mask, in the TA isoforms, a repressive domain at the C-
terminal of the protein present in the a, but not in the b or
g isoforms. In line with this, we ﬁnd that the DN and TA
isoforms are equally capable to bind NF-Y in IP analysis
and to be recruited on Cyclin B2 in ChIPs (Figures 4 and
6); therefore the lack of repression by TA must be due to
intrinsic properties of the extra N-terminal amino acids and
not to lack of promoter recruitment.
The ChIP recruitment assays yielded several intriguing ﬁnd-
ings. First, the lack of association of the EEC C306R mutant to
the 14-3-3s promoter, a bona ﬁde p63 target containing p53
target sequences, conﬁrms recent data obtained with the
TAp63g in in vitro EMSAs (7) and it is a proof that indeed
this is a DNA-binding defective mutant in vivo. In fact, it
involves a residue that is predicted to be required for DNA
binding and corresponds to one of the hotspots of mutations in
DNA-binding defective, tumour derived p53 analogues (5).
Second, the normal recruitment of C306R on Cyclin B2 is
a further indication that direct DNA binding to p53/p63 target
sequences is not required for Cyclin B2 association. Third, the
two AEC mutants tested behave slightly differently in pro-
moter recruitment assays. Note that both the L518F and
Q540L are incapable to associate to NF-Y in solution
(Figure 5), indicating a decrease in afﬁnity for NF-Y.
Q540L involves a residue predicted to be on the surface of
the SAM domain (4,6); it is recruited in vivo, but only on
cotransfected high-copy plasmids. Under the same conditions,
the L518F mutant is negative; this latter mutation is predicted
todeeplyaffecttheoverallstructureoftheSAMdomain(6).In
general, the lack of NF-Y binding of AEC mutants is in accor-
dance with the lack of recruitment and the lack of repression
(Figures 3 and 5). Fourth, AEC mutants have a normal DNA-
binding domain and they are perfectly capable to associate
14-3-3s; hence, the negative data in Cyclin B2 ChIP assays
reinstate that binding is not elicited through a speciﬁc DNA
element within the promoter. Finally, an unexpected ﬁnding
emerging from the repression assays was that the EEC C306R
not only lost this capacity (Figure 3), but even activated tran-
scription, behaving as a gain of function mutant. This estab-
lishes that AEC and EEC have opposite transcriptional effects
in terms of CCAAT-containing promoters. Interestingly, this
is also the case for p53 tumour-derived mutants in the DNA-
binding domain (S. d’Agostino, G. Blandino and G. Piaggio,
personal communication).
The fundamental question is what is the role of p63 asso-
ciation to G2/M promoters? A hint might come from the p53
experiments. DNA-damage rapidly ‘activates’ p53 on
repressed promoters, as checked by p300 and PCAF-
mediated acetylation, triggering a set of events leading to
HDACs recruitment, histones deacetylation, coactivators
release and promoter shut-off (20). Similarly, p73-mediated
recruitment of HDACs was reported on PDGF-b-R (43). The
p53pathway isphysiologically linkedtogenotoxic stress,inas
much as the involvement of p63 and p73 in response to DNA-
damage has been detailed (45–47), genetic data point to p63 as
an ectodermal regulator and a master gene of stem cells of
multilayered epithelia, at the crossroad between self-renewal
and differentiation. The RT–PCR and ChIP results of differ-
entiated HaCaT, in which repressed promoters are associated
by p63 and by the NF-Y activator (Figure 7), strongly suggest
that p63 is permissive for transcription in growing cells, but
behaves as a repressor of key cell-cycle controlling genes in
differentiated cells. In selected cellular contexts, it would act
as a sensor and transducer of developmental and environmen-
tal signals of differentiation versus growth. If the p53 para-
digm is followed, we should expect to ﬁnd a plethora of yet
unknown post-translational modiﬁcations in p63, and possibly
in NF-Y, regulating the access of coactivators and corepres-
sors to different classes of promoters in different growth con-
ditions. The mechanistic details of this will only be understood
when such modiﬁcations, and their effects onthe protein struc-
ture, will be available. One intriguing possibility is that the
subversion of the repressive, on cell-cycle genes, or activating,
on growth arrest genes, behaviours by AEC mutations favour
unrestricted growth of keratinocytes stem cells, resulting in an
early wasting of their proliferative potential. Indeed, colony
formation assays support the idea that AEC mutants lose the
capacity to suppress growth (16). Finally, it is important to
reinstate that DNp63a activates speciﬁc set of genes through
additional activation domains [(16,19) and B. Testoni and
936 Nucleic Acids Research, 2006, Vol. 34, No. 3R. Mantovani, manuscript in preparation]. The panel of vali-
dated bona ﬁde p63 targets in keratinocytes, as observed not
only in overexpression assays, but most importantly, in in vivo
ChIPs experiments, is still extremely skinny (48–51). A full
understanding of the molecular mechanisms underlying the
AEC mutant phenotype will have to await a considerable
lengthening of this list, and the functional analysis of
AEC-derived p63 on their expression.
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